Qiagen Marseille SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Qiagen Marseille Issues FY 2013 Revenue Guidance; Sells Ipsogen Inc to Qiagen Inc
Qiagen Marseille announced that it expects a decrease in revenue in fiscal year 2013 due to a transfer price lower than the final customer price list of Qiagen Marseille products and the incidence of revenues generated in December, 2012 by the implementation of the Distribution agreement and, especially other ancillary agreements that were also signed to strengthen synergies between the Company and the Qiagen Group. The Company also announced that it sold its subsidiary Ipsogen Inc. to Qiagen Inc. on January 1, 2013 for a global amount of USD 3.7 million.
Latest Key Developments in Biotechnology
- Lion Biotechnologies announces closing of underwritten common stock offering
- Kite Pharma submits investigational new drug application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
- Jaguar Animal Health, Inc initiates filing of first new Animal Drug application with FDA
- Qiagen Marseille receives offer from management team to acquire some of its assets
- Share this
- Digg this